Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
HROWL
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q2.23
N/A
-0.14
vs NA
Q3.23
N/A
-0.13
vs NA
Q4.23
N/A
NA
vs -0.00
Q1.24
N/A
NA
vs -0.22
Q2.24
N/A
NA
vs -0.14
Q3.24
N/A
NA
vs -0.13
Q4.24
N/A
-490336.20
vs NA
Q1.25
N/A
-0.50
vs NA
Q2.25
N/A
0.01
vs NA
Q3.25
N/A
0.18
vs NA
Sales Growth
YoY
Current
Estimates
Q2.23
+44%
33.5M vs 23.3M
Q3.23
+50%
34.3M vs 22.8M
Q4.23
+79%
36.4M vs 20.3M
Q1.24
+33%
34.6M vs 26.1M
Q2.24
+46%
48.9M vs 33.5M
Q3.24
+44%
49.3M vs 34.3M
Q4.24
+84%
66.8M vs 36.4M
Q1.25
+38%
47.8M vs 34.6M
Q2.25
+33%
65.2M vs 48.9M
Q3.25
+52%
74.8M vs 49.3M
Return on Equity
QoQ
Q2.23
-19%
-0.19
vs -0.30
Q3.23
-6%
-0.06
vs -0.19
Q4.23
-13%
-0.13
vs -0.06
Q1.24
-23%
-0.23
vs -0.13
Q2.24
-11%
-0.11
vs -0.23
Q3.24
-7%
-0.07
vs -0.11
Q4.24
+10%
0.1
vs -0.07
Q1.25
-31%
-0.31
vs 0.1
Institutionnal Ownership
Forecast
719%2026-Revenue
391%2026-EPS
437%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available
Quote Panel
Key Metrics
Relative Strength
HROWL
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.
NASDAQ
Unprofitable
Unprofitable
-0.00Â ( -0.01%)
Relative Strenght
51
Volume Buzz
-87%
Earning Acce
No
Dist 52w H.
1%Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How HROWL compares to sector?